Exhibits G protein-coupled serotonin receptor binding activity; GTPase activating protein binding activity; and protein domain specific binding activity. Involved in several processes, including positive regulation of NAD(P)H oxidase activity; positive regulation of superoxide anion generation; and positive regulation of vascular smooth muscle cell proliferation. Localizes to membrane raft; plasma membrane; and zymogen granule. Predicted to colocalize with Golgi membrane and endoplasmic reticulum membrane. Biomarker of hypertension. Orthologous to human GNAI3 (G protein subunit alpha i3); PARTICIPATES IN angiotensin II signaling pathway via AT2 receptor; endothelin signaling pathway; epidermal growth factor/neuregulin signaling pathway; INTERACTS WITH (+)-alpha-tocopherol; 2,6-dinitrotoluene; 3H-1,2-dithiole-3-thione.
diphenyleneiodonium affects the reaction [Glucose results in decreased expression of GNAI3 protein], diphenyleneiodonium inhibits the reaction [Streptozocin results in decreased expression of GNAI3 protein]
Acetylcysteine inhibits the reaction [Glucose results in decreased expression of GNAI3 protein], Acetylcysteine inhibits the reaction [Streptozocin results in decreased expression of GNAI3 protein]
manganese(III)-tetrakis(4-benzoic acid)porphyrin inhibits the reaction [Peroxynitrous Acid results in decreased expression of GNAI3 protein], Uric Acid inhibits the reaction [Peroxynitrous Acid results in decreased expression of GNAI3 protein]
CAV3 mutant form inhibits the reaction [Progesterone results in decreased expression of GNAI3 protein], Cholesterol inhibits the reaction [Progesterone results in decreased expression of GNAI3 protein]
8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [S-Nitroso-N-Acetylpenicillamine results in decreased expression of GNAI3 protein] more ...
Acetylcysteine inhibits the reaction [Streptozocin results in decreased expression of GNAI3 protein], diphenyleneiodonium inhibits the reaction [Streptozocin results in decreased expression of GNAI3 protein]
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Gene-Chemical Interaction Annotations
